Acrivon CEO sells 14K shares for tax withholding

Acrivon Therapeutics, Inc. (ACRV) reported that President and CEO Dr. Peter Blume-Jensen, who is also a director, and co-founder and EVP Business Operations Dr. Kristina Masson, also a director, filed a joint Form 4.

Rhea-AI Filing Summary

Acrivon Therapeutics, Inc. (ACRV) reported that President and CEO Dr. Peter Blume-Jensen, who is also a director, and co-founder and EVP Business Operations Dr. Kristina Masson, also a director, filed a joint Form 4. On 2026-08-25, 14,036 shares of Common Stock were sold at a weighted average price of $2.2064 per share to satisfy mandatory tax withholding upon vesting of restricted stock units. Following this transaction, Dr. Blume-Jensen held 2,230,052 shares directly, and there were 385,859 shares held indirectly through securities held by Dr. Masson. Each spouse disclaims beneficial ownership of the other’s reported holdings except to the extent of their pecuniary interest.

Insider Trade Summary

Net Seller: 14,036 shares

Net Sell 2 txns

Insider Blume-Jensen Peter, Masson Kristina

Role President and CEO | EVP - Business Operations

Sold 14,036 shs ($31K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2, F3	14,036	$2.2064	$31K
holding	Common Stock F4	--	--	--

Holdings After Transaction: Common Stock — 2,230,052 shares (Direct); Common Stock — 385,859 shares (Indirect, See Footnote)

Footnotes (4)

1. F1. Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.
2. F2. The price reported in Column 4 above reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $2.17 to $2.25, inclusive. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in footnote 2 of this Form 4.
3. F3. These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.
4. F4. These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Key Figures

Shares sold: 14,036 shares of Common Stock Weighted average sale price: $2.2064 per share Sale price range: $2.17 to $2.25 per share +3 more

6 metrics

Shares sold 14,036 shares of Common Stock Sold on 2026-08-25 to satisfy mandatory tax withholding upon RSU vesting

Weighted average sale price $2.2064 per share Weighted average price for the 14,036 shares sold on 2026-08-25

Sale price range $2.17 to $2.25 per share Range of individual trade prices included in the weighted average sale

Direct holdings after transaction 2,230,052 shares Common Stock held directly by Dr. Peter Blume-Jensen following the sale

Indirect holdings after transaction 385,859 shares Common Stock held indirectly through securities held by Dr. Kristina Masson

Net shares sold 14,036 shares Net sell direction for reported non-derivative transactions in this Form 4

Key Terms

restricted stock units, mandatory tax withholding, weighted average sale price, pecuniary interest

4 terms

restricted stock units financial

"upon vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

mandatory tax withholding financial

"sold automatically to satisfy the mandatory tax withholding requirement"

weighted average sale price financial

"The price reported ... reflects the weighted average sale price"

pecuniary interest financial

"disclaims beneficial ownership ... except to the extent of her pecuniary interest"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ACRV report on this Form 4?

Acrivon Therapeutics, Inc. (ACRV) reported a sale of 14,036 shares of Common Stock by President and CEO Dr. Peter Blume-Jensen on 2026-08-25, executed to satisfy mandatory tax withholding upon vesting of restricted stock units.

At what price were the ACRV shares sold in the reported transaction?

The 14,036 ACRV shares were sold at a weighted average price of $2.2064 per share. The filing states the trades occurred in multiple transactions at prices ranging from $2.17 to $2.25 per share.

How many ACRV shares does Peter Blume-Jensen hold after the transaction?

After the reported sale, Dr. Peter Blume-Jensen held 2,230,052 shares of ACRV Common Stock directly. The filing also reports 385,859 shares held indirectly through securities held by his spouse, Dr. Kristina Masson.

Why were the ACRV shares sold in this Form 4 filing?

The filing states the 14,036 ACRV shares were sold automatically to satisfy mandatory tax withholding requirements that arose upon the vesting of restricted stock units, indicating the sale was for tax purposes rather than discretionary trading.

How are the indirect ACRV holdings between Blume-Jensen and Masson characterized?

The filing explains that some ACRV securities are held by Dr. Blume-Jensen and some by his spouse Dr. Kristina Masson. Each disclaims beneficial ownership of the other’s securities except to the extent of their respective pecuniary interest.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/27/2026 - 04:15 PM EDT Accepted by SEC EDGAR 08/27/2026 - 04:14 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Blume-Jensen Peter

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/25/2026		S(1)		14,036	D	$2.2064(2)	2,230,052	D(3)
Common Stock								385,859	I	See Footnote(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

Blume-Jensen Peter

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

1. Name and Address of Reporting Person^*

Masson Kristina

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP - Business Operations

Explanation of Responses:

1. Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

2. The price reported in Column 4 above reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $2.17 to $2.25, inclusive. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in footnote 2 of this Form 4.

3. These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.

4. These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

	/s/ Adam D. Levy, Attorney-in-Fact for Peter Blume-Jensen	08/27/2026
	/s/ Adam D. Levy, Attorney-in-Fact for Kristina Masson	08/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)